The IIFL Securities Report: Buy Sanofi India - June 10

IIFL Securities has issued a buy recommendation for Sanofi India, setting a target price of Rs 10,750, indicating a potential upside of approximately 5.7%. The current market price of Sanofi India stands at Rs 10,164.6, suggesting a potential gain for investors who follow the recommendation. The rationale behind the recommendation and the factors driving the positive outlook for the stock are not explicitly mentioned in the provided information.

About Sanofi India:

Sanofi India, a subsidiary of the French pharmaceutical giant Sanofi, is a leading healthcare company in India. Established in 1956, it manufactures and markets a wide range of prescription and over-the-counter medicines, vaccines, and consumer health products. The company has a strong presence in key therapeutic areas such as cardiology, diabetes, oncology, and vaccines. Sanofi India is committed to providing innovative and affordable healthcare solutions to improve the lives of patients in the country.

52 Week Price Trend:

Sanofi India (NSE: SANOFI) is currently trading at Rs 10164.6, hovering near its 52-week high of Rs 9380. Despite facing headwinds in the past, the stock has experienced significant growth, rising from its 52-week low of Rs 5329.7. This reflects the company's strong performance in the pharmaceutical industry and its commitment to innovation and patient care.

Stratzy's MOST Analysis:

Stratzy's MOST framework assigns SANOFI an AA- rating, indicating medium fundamental risk. This rating is derived from the assessment of four pillars: Management (A), Outlook (A), Safety (AA), and Trend (A-). The A rating in Management suggests strong leadership and execution capabilities, while the A rating in Outlook implies a positive growth trajectory. The AA rating in Safety indicates low financial risk, and the A- rating in Trend reflects a positive momentum in the company's performance. Overall, SANOFI's AA- rating suggests a solid foundation with moderate risk factors.

Company's Fundamentals:

Sanofi India (NSE: SANOFI), a pharmaceutical firm, has a Stock PE ratio of 35.26, indicating that its share price is 35.26 times its earnings per share. Its PB Ratio of 20.51 suggests that its market value is 20.51 times its book value. The company's Dividend Yield of 2.15% shows that it distributes 2.15% of its share price as dividends to shareholders. These ratios indicate that Sanofi India is relatively expensive compared to peers based on earnings and book value, but offers a moderate dividend yield.

Fundamental and Technical information provided in this blog were last updated on 08 Jun, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.